<DOC>
	<DOCNO>NCT02381132</DOCNO>
	<brief_summary>The purpose study explore clinical characteristic oral MNK155 Norco® 7.5mg/325mg use treatment moderate severe post operative pain .</brief_summary>
	<brief_title>A Randomized , Open Label , Prospective Study Explore Clinical Characteristics Oral MNK155 Norco 7.5mg/325 When Used Treatment Moderate Severe Post Operative Pain</brief_title>
	<detailed_description>This single center , open label , prospective , randomize study adult post operative subject expect require oral opioid analgesia least 48 hour surgery . The main study drug interest study MNK 155 . Norco® 7.5mg/325mg utilized active comparator . Subjects least 18 year age schedule undergo elective surgery . The following surgical type allow , although list inclusive : - Abdominal surgery - Soft tissue surgery - Orthopedic surgery - Spine surgery - Genitourinary surgery</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<criteria>1 . Subjects provide write informed consent prior enrollment . 2 . Male female 18 year age old . 3 . Subjects schedule undergo elective general surgery include , limited follow surgical type : Abdominal surgery Orthopedic surgery Spine surgery Genitourinary surgery 4 . Subjects classified American Society Anesthesiologists ( ASA class IIII ) . 5 . Female subject eligible follow apply : Not pregnant ( subject child bear potential must negative beta human chorionic gonadotropin ( βhCG ) pregnancy test surgery ) ; Not lactate ; Not plan become pregnant within duration study ; 6 . Subjects expect acute pain require oral opioid analgesic least 48 hour post operative period ( either inpatient outpatient ) . 7 . Subjects willing capable understanding cooperating requirement study . 8 . Subjects able understand communicate English . 1 . Subjects medical condition , Investigator 's opinion , could adversely impact subject 's participation , safety , conduct study limit history severe renal hepatic impairment , severe active hepatic disease , clinically significant medical condition may preclude safe study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>